Since GKRP is expressed exclusively in the liver, this compound selectively activates hepatic GCK without affecting pancreatic beta-cells, thereby lowering fasting glucose levels with a reduced risk of hypoglycemia [76]. The gene discussed is GCK; the disease is Hypoglycemia.